白雲山(600332.SH):頭孢地尼顆粒收到藥品註冊證書
格隆匯11月25日丨白雲山(600332.SH)公佈,公司控股子公司廣州白雲山天心製藥股份有限公司(簡稱“天心製藥”)收到國家藥品監督管理局核准簽發關於頭孢地尼顆粒(50mg)的《藥品註冊證書》。
頭孢地尼顆粒屬第三代頭孢類抗生素,主要是通過抑制細菌細胞壁的合成而起到殺菌作用,是一種廣譜的抗菌素,於2002年在中國獲批上市。適用於治療對頭孢地尼敏感的葡萄球菌屬、鏈球菌屬、肺炎球菌、消化鏈球菌、丙酸桿菌、淋病奈瑟氏菌、卡他莫拉菌、大腸埃希菌、克雷伯菌屬、奇異變形桿菌、普魯威登斯菌屬、流感嗜血桿菌等菌株所引起的感染,是一種同時適用於成人與兒童的抗生素。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.